Cytovac is a clinical-stage biopharmaceutical company dedicated to the discovery and development of novel immunotherapies to treat cancer with a primary focus towards orphan diseases.
In general, Cytovac intends to develop each orphan oncology drug program to the highest value inflection point possible. Cytovac will seek to enter into global development and license agreements following clinical Phase II POC or later. For larger indications where substantial more resources are needed Cytovac might enter into global development and license agreements following Phase I or even earlier.
The Interim Report Q1 2019 is now ready in English and in Swedish